Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth

Stock Track

May 06

UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.

The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.

The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1174571892"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174571892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174571892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174571892","market":"sg","top_or_hot":-1,"title":"Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth","media":"Stock Track","content":"<p>UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.</p><p>The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.</p><p>The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"乌龙制药","start_time":0,"source_url":"","article_id":"1174571892","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174571892","pubTimestamp":1778073147,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药"},"translate_title":"个股追踪|UroGen Pharma盘前飙升5.67%，Q1盈利强劲，营收增长152%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":1},"content_text":"UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}